Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, Dan, Hahn, Margaret, Correll, Christoph U., Fink‐Jensen, Anders, Russell, Anthony W., Bak, Nikolaj, Broberg, Brian V., Larsen, Julie +5 more·2019·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.13522

Cited by (144)

Items 101–144 of 144

  1. Therapeutic management of obesity induced by antipsychotic drugs
    Wojciech Merk, Michał Lew‐Starowicz · 2021 · Wiedza Medyczna
  2. GLP-2 attenuates antipsychotics’ adverse metabolic effects
    Sandra Pereira, Margaret Hahn · 2025 · Nature Metabolism
  3. Latest findings challenge behavioural approaches to the management of antipsychotic-induced weight gain
    Steve R Kisely, Dan J. Siskind, Helene Speyer · 2025 · BJPsych Open
  4. The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study
    Kristina Brenisin, Florence‐Emilie Kinnafick, James A. King, Louise Millard, Donna Arya, Elizabeth Hodgson, Michelle Huggins, Andrew Simmons-Roberts, Martin O'Dowd, Nick Rayment et al. · 2025 · JMIR Research Protocols
  5. Atypical Antipsychotics‐Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention
    Aixiao Xia, Qi Jin, Shuwei Ke, Hanbing Li, Junwei Wang · 2025 · Journal of Applied Toxicology
  6. Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients
    Tinghui Liu, Chia-Hsuan Hsu, Jheng‐Yan Wu, Po‐Yu Huang, Chih‐Cheng Chang, Chih-Cheng Lai · 2025 · European Neuropsychopharmacology
  7. The role of 5-HT3 receptors in schizophrenia and associated depressive and addictive comorbidities
    Radomír Jůza, Anna Więckowska, Iveta Vojtěchová, Kamil Kuča, Ondřej Soukup, Jan Korábečný, Tomáš Petrásek · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  8. Antipsychotics and schizophrenia, and their relationship to diabetes
    Clare Alexandra Whicher, Sarah Brewster, Richard I. G. Holt · 2019 · Practical Diabetes
  9. Managing glucose-related adverse events of antipsychotics is worth the effort
    Caroline Fenton, Connie Kang · 2021 · Drugs & Therapy Perspectives
  10. Evaluating the Effectiveness of Joint Specialist Case Conferences in Improving Diabetes Control in Patients With Schizophrenia on Clozapine
    Yu Zheng, Gideon Meyerowitz‐Katz, Sian Bramwell, Rajini Jayaballa, Yolinda Assur, Deepali Vasani, Ramanathan Ganapathy, GLEN F. MABERLY, Vlasios Brakoulias · 2022 · The Journal of Nervous and Mental Disease
  11. Lithium plus Olanzapine as One of the Most Effective Combinations for Bipolar Disorder. A Case Report and a Concise Review of the Literature
    Aitzol Miguélez Rodríguez, Xabier Pérez de Mendiola Etxezarraga · 2021
  12. Schizophrenia
    Robert Hudak, Jessica M. Gannon · 2022 · Current clinical practice
  13. Review for "Monitoring for Myocarditis during Treatment Initiation with Clozapine"
    2021 · Publons reviews and discussion
  14. Review for "Monitoring for Myocarditis during Treatment Initiation with Clozapine"
    2021 · Publons reviews and discussion
  15. Lithium Plus Olanzapine: One of the Most Effective Combinations for Bipolar Disorder: A Case Report and a Concise Review of the Literature
    Aitzol Miguélez Rodríguez, Xabier Pérez de Mendiola Etxezarraga · 2021 · Current Psychiatry Research and Reviews
  16. Review for "Monitoring for Myocarditis during Treatment Initiation with Clozapine"
    2021 · Publons reviews and discussion
  17. Review for "Monitoring for Myocarditis during Treatment Initiation with Clozapine"
    2021 · Publons reviews and discussion
  18. Diabètes pharmaco-induits : quatre classes médicamenteuses au cœur de notre pratique clinique
    André Jacques Scheen, Bruno Fève · 2022 · Médecine des Maladies Métaboliques
  19. PHARMACOLOGICAL ADD-ON TREATMENTS IN MANAGING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
    Ionuț-Dragoș Rădulescu, Mirona Letiția Dobri, Codrina Moraru, Petronela Nechita, Ciprian Vlad, Cezar Ionuț Bichescu · 2023 · European Conference of Psychiatry and Mental Health "Galatia"
  20. Current treatment options in early-onset psychosis
    Anne Katrine Pagsberg, Marianne Melau · 2023 · Elsevier eBooks
  21. Mental Disorders and Diabetes
    Najma Siddiqi, Marietta Stadler, Richard I. G. Holt · 2024 · Wiley eBooks
  22. Case 8: From prodrome to psychosis: early-onset schizophrenia
    Jeffrey R. Strawn, Stephen M. Stahl · 2023 · Cambridge University Press eBooks
  23. Chapter 27. Olanzapine
    Jacob S. Ballon, Julio Cesar Nunes, Khalid Salaheldin · 2024 · American Psychiatric Association Publishing eBooks
  24. Chapter 53. Treatment of Schizophrenia
    Mary F. Brunette, Jacob S. Ballon, Samantha A. Gnanasegaram, Agnieszka Kalinowski, William R. Keller, Jeffrey D. Reed, Doug Noordsy · 2024 · American Psychiatric Association Publishing eBooks
  25. Metabolic syndrome in adolescents with mental disorders: diagnostics, prevention and treatment
    Т. I. Prusova, O. V. Lepik, Dmitry N. Kosterin, Yu. A. Yakovleva, Mikhail Yu. Popov · 2024 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  26. Response to “Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review”
    Sigrid Breit, Daniela Hubl · 2025 · Psychoneuroendocrinology
  27. The effect of weight loss on brain age in schizophrenia spectrum disorders
    Vittal Korann, Nicolette Stogios, Karen S. Ambrosen, Gary J. Remington, Ariel Graff‐Guerrero, Bjørn Hylsebeck Ebdrup, Margaret Hahn, Sri Mahavir Agarwal · 2025 · PLOS mental health.
  28. Hyperglycémies iatrogènes en dehors du virus de l’immunodéficience humaine
    P. Treca, C. Amouyal · 2025 · EMC - Endocrinologie - Nutrition
  29. Psychopharmakotherapie: Grundfertigkeiten
    Jan Philipp Klein, Eva Margaretha Klein · 2025 · Springer eBooks
  30. Beyond Clozapine
    Cherdpong Choenklang, Schawanya K. Rattanapitoon, Nav La, Nathkapach K Rattanapitoon · 2026 · Journal of Clinical Psychopharmacology
  31. Association of incretin therapy with self-harm behaviors in people with psychiatric conditions: A retrospective cohort study
    Hailey Kalamaras, Raechel T. White, Scott A. Coon, Matthew Perkel, Amre A Elmaoued · 2026 · Journal of Psychopharmacology
  32. Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis
    Anna Zierotin, Jennifer Murphy, Anja Stano, Michael John Norton, David Cotter, Mary D Cannon, K. O’Connor, Brian N. O'Donoghue, Mary Clarke · 2026 · Schizophrenia Bulletin
  33. Managing metabolic syndrome in bipolar disorder: multidisciplinary monitoring and treatment strategies
    Jorge César Correia, Hélène Richard-Lepouriel, Anne Chalut-Carpentier, Zoltan Pataky · 2026 · Frontiers in Psychiatry
  34. Effectiveness of GLP-1RA vs metformin for diabetes prevention in antipsychotic-treated patients
    Ting-Hui Liu, Chung-Han Lee, Chia-Yu Liu, Jheng‐Yan Wu, Ya‐Wen Tsai, Pei‐Hsin Kao, Chih‐Cheng Lai · 2026 · European Neuropsychopharmacology
  35. Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review
    Catarina Domingues, Maria João Ferreira, Rosa de Pinho · 2026 · Cureus
  36. Multi-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link
    Ngo Cheung · 2026 · Cureus
  37. GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction
    Joshua Reitz, Daniel B. Rosoff, Pál Pacher, Falk W. Lohoff · 2026 · Biological Psychiatry Global Open Science
  38. Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia
    Nouraiz Abbas, Adil Ahmed Memon, Rumaisa Zulfiqar, Aqsa Zahoor Noon, Syed Mohamin Abbas Shah, Khadija Panhwar, Zehra Sadia, Muhammad Saad Khan, Muhammad Bilal Akbar, Sana Iftikhar et al. · 2026 · Journal of Clinical Psychopharmacology
  39. Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework
    Michael Kaczynski, Rina Maria Zureikat, Matthew Roman Kaczynski, Ryszard Sitarz, Hanna Karakuła‐Juchnowicz · 2026 · Biomedicines
  40. Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study
    Laura Giraldi, Jón Trærup Andersen, Jonas Jespersen, Christoffer Storm Baden, Cilius Esmann Fonvig, Troels Riis, Kim Dalhoff, Jens‐Christian Holm, Anders Fink‐Jensen, Anne Katrine Pagsberg et al. · 2026 · BMJ Open
  41. Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
    Samuel Governor, David M. Davila-Garcia, Eliut Rivera-Segarra, Lindsey M. Filiatreau, Nelmit Tollinchi-Natali, Ekow Essien, Osamah Altaee, Prince Otchere, Leopoldo J. Cabassa, Víctor G. Dávila‐Román · 2026 · Journal of the American Heart Association
  42. Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis
    Lingyan Zhou, Ying Zhang, Chao Shen, Fengbo Wu · 2026 · European Journal of Clinical Pharmacology
  43. Efficacy and safety of GLP-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a systematic review and meta-analysis
    Adam Gędek, Szymon Modrzejewski, Krzysztof Polański, Laura Waśniewska, Patricio Molero, Adam Wichniak, Monika Dominiak, Roger S. McIntyre · 2026 · European Neuropsychopharmacology
  44. Reversibility of Antipsychotic-Induced Dyslipidaemia: A Narrative Review of Switching Strategies, Dose Reduction and Discontinuation
    Sheriffdeen A Adekanmbi, Yetunde Arowora, Yetunde O Soetan, Temebi W Andafa, Chiamaka Njoku, Zulikhat Maruwf · 2026 · Cureus